Dermata Therapeutics, Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, Dermata Therapeutics is in Stage 4, the downtrend phase, now in week 5 (since Sep 22, 2026). It closed at $0.86, 79.3% below its 52-week high and below its 200-day average, which is falling.

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. More about the company

$0.86

+7.42% today

$4.3M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is DRMA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 145w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 145w → S1 1w → S4 6w → S1 3w → S4 2w → S1 5w → S4 4w current

Total tracked: 166 weeks across 7 stage runs.

DRMA among Biotechnology462nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…462	DRMADermata Therapeutics, Inc.	Stage 4 · wk 5	12	−22.9%

vs 52W High

-79.3%

$0.66 lo$4.18 hi

79.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-36.2%

200 DMA: $1.36 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.04x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-22.9%

-34.5%

-31.7%

YTD

-60.4%

-79.2%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 5 · Vol 0.04x

2026-10-21S4

Wk 5 · Vol 0.05x

2026-10-20S4

Wk 5 · Vol 0.04x

2026-10-19S4

Wk 4 · Vol 0.20x

2026-10-16S4

Wk 4 · Vol 0.59x

2026-10-15S4

Wk 4 · Vol 191.14x

2026-10-14S4

Wk 4 · Vol 0.40x

2026-10-13S4

Wk 4 · Vol 0.04x

2026-10-12S4

Wk 3 · Vol 0.04x

2026-10-09S4

Wk 3 · Vol 0.02x

2026-10-08S4

Wk 3 · Vol 0.01x

2026-10-07S4

Wk 3 · Vol 0.01x

Moving averages & range

50 DMA

$1.18

200 DMA

$1.36

52W High

$4.18

52W Low

$0.66

5D Low

$0.80

Resistance levels (recent highs)

20d High

$1.14

60d High

$1.72

120d High

$1.72

250d High

$4.07

Next resistance

+31.9%

to 20d High

ROE

-183.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.0

Dermata Therapeutics: quick answers

What stage is Dermata Therapeutics in?

As of Oct 22, 2026, Dermata Therapeutics (DRMA) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 22, 2026 and is in week 5. What the four stages mean

Is Dermata Therapeutics in an uptrend?

No. Dermata Therapeutics is in a Stage 4 downtrend. It trades 36.2% below its 200-day average, which is falling.

How far is Dermata Therapeutics from its 52-week high?

Dermata Therapeutics closed at $0.86 on Oct 22, 2026, 79.3% below its 52-week high of $4.18. Its 52-week low is $0.66.

How has Dermata Therapeutics performed over the past year?

As of Oct 22, 2026, Dermata Therapeutics is down 79.2% over the past year and down 60.4% so far in 2026.

Which sector and industry is Dermata Therapeutics in?

Dermata Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.